Compulsive buying treatment with topiramate, a case report

Guzman, Carlos Simón; Filomensky, Tatiana Zambrano; Tavares, Hermano

doi:10.1590/s1516-44462007000400020

Cited by 18 publications

(13 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, no comparison was made between improvement pace/rates in each phase, limiting conclusions about continued effect of placebo in active treatment. Grant, Odlaug, Mooney, O’Brien and Kim (2012) completed an open-label study of the effectiveness of memantine (an NMDA-receptor agonist used in the treatment of impulsivity). In the small uncontrolled sample ( N = 9), significant improvements in YBOCS-SV scores between baseline and end of treatment were reported.…”

Section: Resultsmentioning

confidence: 99%

“…This overlap between drug and placebo confidence intervals suggests a non-significant difference between active and placebo CBD drug treatments. The poor methodological quality of the outcome studies of fluvoxamine (Black et al., 1997; Ninan et al., 2000) and memantine (Grant et al., 2012) undermines the large effect size found. Black et al’s (2000) trial revealed the comparable effects of placebo to fluvoxamine.…”

Section: Resultsmentioning

confidence: 99%

“…The promising findings from the controlled study of citalopram (Koran et al., 2003) and uncontrolled studies of topiramate (Guzman et al., 2007), naltrexone (Grant, 2003; Kim, 1998), and memantine (Grant et al., 2012) require further scrutiny under large sample RCT conditions. This comment also applies to substantiate the initial claims regarding the effectiveness of MBSR for CBD (Armstrong, 2012).…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Treatments for compulsive buying: A systematic review of the quality, effectiveness and progression of the outcome evidence

Hague¹,

Hall²,

Kellett³

2016

J Behav Addict

View full text Add to dashboard Cite

Background and aimsThis review appraises the progression and status of the evidence base for the treatment of compulsive buying disorder (CBD), in order to highlight what currently works and to prompt useful future research.MethodsOnline databases ISI Web of Knowledge, PsycINFO, and PubMed via Ovid were searched at two time points. Two quality checklists and an established model of therapy evaluation (hourglass model) evaluated the quality and progression of both psychotherapy and pharmacotherapy treatments for CBD. Uncontrolled effect sizes were calculated and meta-regression analyses were performed regarding treatment duration.ResultsA total of 29 articles met the inclusion criteria, which were divided into psychotherapy (n = 17) and pharmacotherapy treatments (n = 12). Of the 29 studies, only 5 studies have been tested under conditions of high methodological quality. Both forms of treatment had been evaluated in a haphazard manner across the stages of the hourglass model. Although large effects were demonstrated for group psychotherapy and pharmacotherapy, such evidence of effectiveness was undermined by poor study quality and risk of publication bias. Long-term CBD treatment was associated with improved outcome with pharmacotherapy, but not when delivering psychotherapy.DiscussionGroup psychotherapy currently appears the most promising treatment option for CBD. Poor methodological control and sporadic evaluation of specific treatments have slowed the generation of a convincing evidence base for CBD treatment. Defining the active ingredients of effective CBD treatment is a key research goal.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Treatments for compulsive buying: A systematic review of the quality, effectiveness and progression of the outcome evidence

Hague¹,

Hall²,

Kellett³

2016

J Behav Addict

View full text Add to dashboard Cite

show abstract

“…No open or double-blind trials were conducted with this agent to confirm these findings. Two case reports were published on the treatment of CBD with topiramate [43,44]. Topiramate is an active anticonvulsant whose mechanisms of action include potentiation of gamma-aminobutyric acid (GABA) to activate GABA-A receptors and antagonism of glutamate at specific receptors.…”

Section: Naltrexonementioning

confidence: 99%

A Review of Pharmacologic Treatment for Compulsive Buying Disorder

2016

View full text Add to dashboard Cite

At present, no treatment recommendations can be made for compulsive buying disorder. Recent studies have found evidence for the efficacy of psychotherapeutic options, but less is known regarding the best pharmacologic treatment. The purpose of this review is to present and analyze the available published evidence on the pharmacological treatment of compulsive buying disorder. To achieve this, we conducted a review of studies focusing on the pharmacological treatment of compulsive buying by searching the PubMed/MEDLINE database. Selection criteria were applied, and 21 studies were identified. Pharmacological classes reported included antidepressants, mood stabilizers, opioid antagonists, second-generation antipsychotics, and N-methyl-D-aspartate receptor antagonists. We found only placebo-controlled trials for fluvoxamine; none showed effectiveness against placebo. Three open-label trials reported clinical improvement with citalopram; one was followed by a double-blind discontinuation. Escitalopram was effective in an open-label trial but did not show efficacy in the double-blind phase. Memantine was identified as effective in a pilot open-label study. Fluoxetine, bupropion, nortriptyline, clomipramine, topiramate and naltrexone were only reported to be effective in clinical cases. According to the available literature, there is no evidence to propose a specific pharmacologic agent for compulsive buying disorder. Future research is required for a better understanding of both pathogenesis and treatment of this disorder.

show abstract

“…In the first study, compulsivebuying symptoms vastly improved with the medication; in the other one, puzzlingly, relapse rates were the same whether the compulsive buyers had been on medication or on a placebo (Koran, Aboujaoude, Solvason, Gamel, & Smith, 2007;Koran, Chuoung, Bullock, & Smith, 2003). In addition to antidepressants, treatment with mood stabilizers, naltrexone (an opioid antagonist), and Topamax (an anticonvulsant) have been reported (Black, Manahan, & Gabel, 1997;Grant, 2003;Guzman, Filomensky, & Tavares, 2007;Koran, Bullock, Hartson, Elliott, & D'Andrea, 2002). Due to the high incidence of comorbidity in compulsive buyers, it is difficult to determine whether a drug exerts an independent effect on compulsive-buying symptoms distinguishable from its effects on mood, anxiety, and other underlying conditions.…”

Section: Treatment Modalitiesmentioning

confidence: 99%